Form D · Biotechnology
Hepion Pharmaceuticals, Inc.
Red Bank, NJ · CIK 0001583771
Offering snapshot reported Aug 5, 2026 · SEC filing
- Reported sold
- $3.06M Offering amount: $3.06M
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 31, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 5, 2026 | Initial | $3,055,000 | No comparison | 33 | SEC filing |
| Apr 22, 2026 | Initial | $700,000 | No comparison | 11 | SEC filing |
| Jul 24, 2024 | Initial | $2,900,000 | No comparison | 7 | SEC filing |
| Oct 3, 2023 | Initial | $5,000,004 | No comparison | 1 | SEC filing |
| Nov 15, 2022 | Initial | $20,000,000 | No comparison | 8 | SEC filing |
| Mar 27, 2019 | Initial | $1,250,000 | No comparison | 1 | SEC filing |
| Oct 23, 2014 | Initial | $9,000,000 | No comparison | 1 | SEC filing |
| Aug 22, 2014 | Initial | $4,742,648 | No comparison | 19 | SEC filing |
| Feb 14, 2014 | Initial | $3,225,000 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593256
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Not applicable. | None |
Source: Form D, filed Aug 5, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Adams | Director |
| Sireesh Appajosyula | Director |
| Timothy Block | Director |
| John P. Brancaccio | Director |
| John Cavan | Executive |
| Bernard F. Denoyer | Director, Executive |
| Dania Fisher | Director |
| Robert Foster | Director, Executive |
| Todd Hobbs | Executive |
| Bill Hornung | Executive |
| Gary S. Jacob | Director |
| Gary S. Jacobs | Director |
| Kaouthar Lbiati | Director |
| Arnold Lippa | Director |
| Vincent Lo Priore | Director, Executive |
| Chase Lo Priore | Director |
| Christopher Mc Guigan | Director |
| Michael Purcell | Director |
| Anand Reddi | Director |
| James Sapirstein | Director, Executive |
| Gary Stetz | Director, Executive |
| Gary S. Stetz, Ii | Director |
| Petrus Wijngaard | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
34 Shrewsbury Ave. Suite 1 D
Red Bank, NJ, 07701
Phone: (732) 902-4000
Red Bank, NJ, 07701
Phone: (732) 902-4000